Pharmaceuticals company RPG Life Sciences announced Q3FY26 results Revenue: Rs 18,003 lakh against Rs 17,271 lakh during Q3FY25, change 4%. PBT: Rs 2,912 lakh against Rs 4,689 lakh during Q3FY25, change -38%. PAT: Rs 2,213 lakh against Rs 3,493 lakh during Q3FY25, change -37%. EPS: 13.38 for Q3FY26. Ashok Nair, Managing Director, RPG Life Sciences, said: “Q3 reflects continued traction across our core businesses supported by disciplined execution and deliberate portfolio actions. Our Domestic Formulations business delivered growth ahead of the Indian Pharmaceutical Market, recording a growth of 11.8% in 9MFY26 compared to the IPM growth of 8.2%, driven by strong brand performance, improved field effectiveness, and sharper customer engagement. Our approach remains firmly rooted in quality and improving patient outcomes.” “Looking ahead, we remain committed to building a future-ready pharmaceutical enterprise — one that is resilient, innovation-led, and people-first, creating sustainable value for patients, partners, and stakeholders.” Result PDF